American Doctor Working in DR Congo Tests Positive for Ebola

On May 18, 2026, the CDC confirmed that Dr. Peter Stafford, an American missionary physician stationed at Nyankunde Hospital in the city of Bunia, had tested positive for the Bundibugyo ebolavirus [1]. Stafford, who has served with the Pennsylvania-based Christian missions organization Serge since 2023, developed symptoms over the preceding weekend and received his diagnosis late Sunday [2]. Seven Americans, including Stafford, are being transported to Germany for monitoring and specialized medical care [1].

The diagnosis arrived two days after the World Health Organization declared the outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern (PHEIC) — the highest alarm the WHO can sound [3]. As of May 18, health authorities have reported 11 confirmed cases and 336 suspected cases, with at least 88 deaths in DRC's Ituri Province, plus 2 confirmed cases and 1 death in Uganda [4][5].

This is not an ordinary Ebola outbreak. The Bundibugyo strain has no approved vaccine and no proven therapeutic. The two licensed Ebola vaccines — Merck's Ervebo and Johnson & Johnson's two-dose regimen — target the Zaire species and provide little cross-protection against Bundibugyo in animal studies [6]. That fact transforms the calculus for every healthcare worker in the affected region.

The Outbreak: Bundibugyo Virus Returns After Nearly Two Decades

The Bundibugyo ebolavirus was first identified during a 2007 outbreak in western Uganda that sickened 149 people and killed 37, producing a case fatality rate (CFR) of roughly 25% [6]. It has not caused a confirmed outbreak since — until now.

The current epidemic is believed to have originated in the Mongbwalu health zone of Ituri Province, a high-traffic gold mining area, with cases subsequently migrating to Rwampara and Bunia as patients sought medical care [4]. The index case — the first known patient — was a healthcare worker in Bunia who developed fever, hemorrhaging, vomiting, and severe malaise on April 24, 2026, and died at a local medical center [4].

By the time laboratory confirmation identified Bundibugyo virus on May 15, the outbreak had been spreading undetected for approximately three weeks [7]. Two confirmed cases in Kampala, Uganda — individuals who had traveled from eastern DRC — appeared on May 15 and 16, demonstrating cross-border transmission [3].

Source: WHO / CDC Outbreak Records

Data as of May 18, 2026CSV

The DRC has experienced 17 Ebola outbreaks since the virus was first discovered in the country in 1976. The most devastating was the 2018–2020 Kivu epidemic, which produced 3,470 cases and 2,287 deaths across North Kivu and Ituri provinces [8]. The current Ituri outbreak is already larger than several previous outbreaks in confirmed and suspected case counts, and unlike most prior DRC outbreaks, it involves a strain against which the existing medical countermeasures were not designed.

No Vaccine, No Proven Treatment: Why Existing Tools Don't Apply

The two approved Ebola vaccines were developed in response to the Zaire ebolavirus species, which has caused the majority of outbreaks and carries the highest fatality rates — 88% in the original 1976 Yambuku outbreak, 66% during the Kivu epidemic, and 70% in the 2025 Kasai outbreak [8][9].

Ervebo (rVSV-ZEBOV), manufactured by Merck, demonstrated 84% real-world effectiveness during the 2018–2020 DRC outbreak when given 10 or more days before symptom onset, according to a retrospective study published in The Lancet Infectious Diseases [10]. Among vaccinated patients who did develop Ebola, 25% died compared to 63% of unvaccinated patients [11]. But these results apply exclusively to the Zaire strain.

Animal studies of Ervebo against Bundibugyo virus have shown limited cross-protection [6]. Several experimental candidates — including Mapp Biopharmaceutical's MBP 134 and Auro Vaccines' VesiculoVax — have demonstrated efficacy against Bundibugyo in non-human primates, but none have received emergency use authorization [6]. Oxford University and Moderna are collaborating on a broad-spectrum vaccine funded by CEPI and the EU that would target Bundibugyo, Sudan, Zaire, and Marburg viruses, and Chinese researchers have published data on an mRNA candidate covering three strains, but neither is close to field deployment [6].

This means responders are relying on the basics: identifying and isolating patients, tracing contacts, and ensuring safe burial practices [6]. It also means healthcare workers like Dr. Stafford face the virus without the pharmacological safety net that existed during recent Zaire-strain outbreaks.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output on Ebola vaccines surged after the 2014 West Africa crisis, peaking at over 7,100 publications in 2021, but has declined since — falling to approximately 3,500 papers in 2025 [12]. The focus of that research has been overwhelmingly on Zaire-strain countermeasures, leaving Bundibugyo as what one epidemiologist called "a neglected cousin" [6].

Evacuation: Who Gets Out, and How

When Dr. Stafford tested positive, the immediate response involved transporting him and six other high-risk American contacts to Germany for care [1]. His wife, Dr. Rebekah Stafford, and another physician, Dr. Patrick LaRochelle, remain asymptomatic but are in quarantine and part of the evacuation group [2].

The decision to evacuate to Germany rather than the United States reflects both logistical and capacity realities. During the 2014–2016 West Africa outbreak, at least 11 Ebola patients were treated at U.S. biocontainment facilities, primarily at Emory University Hospital, the University of Nebraska Medical Center, and the NIH Clinical Center [13]. By early 2015, the U.S. had expanded to a network of 51 Ebola treatment centers across 16 states with 72 available beds [14]. A public-private partnership also established biocontainment units at Dobbins Air Reserve Base in Georgia to support medical evacuation [14].

Whether that capacity remains fully operational in 2026, after a year and a half of budget cuts and reorganization at the CDC and USAID, is an open question. The CDC has experienced significant staffing reductions, and USAID's DRC mission was shuttered in 2025 [7][15].

The evacuation also highlights a longstanding disparity. International organizations like WHO and MSF maintain evacuation protocols for their own staff, but the same infrastructure is rarely available to Congolese healthcare workers [16]. During the 2014 West Africa epidemic, the vast majority of the more than 200 healthcare worker deaths were local staff who lacked the organizational backing — and medevac guarantees — that international workers received [16].

The Case For and Against Western Evacuations

The decision to evacuate international workers to high-income countries for treatment has always carried political weight in outbreak zones.

Proponents argue that medevac guarantees are essential to maintaining the pipeline of international responders. During the 2014 crisis, the knowledge that evacuation was available if needed helped recruit thousands of foreign healthcare workers to West Africa — workers who brought specialized skills and resources that local health systems lacked [14]. Without that assurance, aid organizations would struggle to deploy staff into active outbreak zones.

Critics raise several counterpoints. First, the resources devoted to evacuating and treating a single Western patient — specialized transport aircraft, biocontainment units, weeks of intensive care — could fund significant local capacity. Second, the optics of airlifting foreign workers to European hospitals while Congolese patients die in overcrowded local facilities can undermine community trust in the response. During the Kivu outbreak, community distrust of international responders contributed to attacks on Ebola treatment centers and the deaths of response workers [17]. Third, some global health scholars argue that prioritizing evacuation over investment in local treatment capacity perpetuates a two-tier system that leaves African healthcare systems weaker in the long run.

The counterargument is that these are not mutually exclusive: organizations can both evacuate their staff and invest in local systems. MSF, for instance, has maintained evacuation capability while also operating the largest field treatment programs in multiple outbreaks [16].

Armed Conflict: The Outbreak Within an Outbreak

Eastern DRC has been destabilized by armed conflict for decades. More than a dozen armed groups operate in Ituri and neighboring provinces, including the Allied Democratic Forces (ADF) and M23 [17]. The DRC ranks fourth globally for internally displaced persons, with 5.2 million people displaced as of 2025 [18].

Source: UNHCR Population Data

Data as of Dec 31, 2025CSV

This displacement directly undermines outbreak containment. Violence in Ituri has limited access for health workers, disrupted contact tracing, restricted the movement of surveillance teams, and hindered the secure transport of laboratory samples [17]. Since January 2025, there have been 44 attacks on healthcare facilities in Congo and 742 incidents affecting humanitarian workers [17].

The practical result is delayed case detection. The current outbreak appears to have circulated undetected for approximately three weeks before laboratory confirmation on May 15 [7]. In stable countries with functioning surveillance systems — such as Nigeria during the 2014 crisis, where the first imported case was detected and contained within days — that delay would be substantially shorter. Each day of undetected transmission in a conflict zone means additional chains of infection that become exponentially harder to trace and break.

The DRC government announced on May 18 that it would open three Ebola treatment centers in Ituri to support the response [19]. But building treatment capacity in an active conflict zone requires security guarantees that have historically proven unreliable.

U.S. Funding: A Diminished Footprint

The United States was the single largest funder of the global Ebola response during and after the 2014 West Africa crisis. In FY2015, Congress appropriated $5.4 billion in emergency Ebola funding across multiple agencies [14]. That funding built surveillance networks, trained health workers, and established the laboratory infrastructure that has been used in subsequent outbreaks.

The current funding picture is markedly different. President Trump's dismantling of USAID in 2025 cut billions in global health aid [15]. U.S. foreign spending on global health initiatives dropped by nearly 57% after USAID was restructured and smaller aid programs were eliminated [15]. Specific Ebola-related contracts worth $1.6 million out of $2.2 million in prevention funding were cut, according to reporting by PolitiFact and NPR [7][15].

The State Department has disputed that these cuts have affected Ebola response capacity. "It is false to claim that the USAID reform has negatively impacted our ability to respond to Ebola," a spokesperson told NPR, adding that funding and support to combat Ebola would continue [7].

Public health experts, however, have pointed to concrete consequences. The CDC's field presence in DRC has been reduced. The USAID DRC mission — which served as a hub for health program coordination — was closed [7]. Former CDC officials have noted that early detection systems built with post-2014 funding require sustained investment to function, and that the current outbreak's three-week detection delay may reflect degraded surveillance capacity [7].

The CDC announced on May 17 that it was mobilizing an international response, including enhanced travel screening and entry restrictions for travelers from affected regions [20]. Whether the agency has the staffing and budget to mount a response comparable to 2018–2020 remains to be seen.

What Happens Next

The WHO's PHEIC declaration triggers a set of international coordination mechanisms, including recommendations for enhanced surveillance at borders, resource mobilization, and accelerated research into Bundibugyo-specific countermeasures [3]. The Emergency Committee noted several factors driving the declaration: cross-border spread to Uganda, the absence of approved vaccines or therapeutics for this strain, the conflict-affected environment, and high population mobility in the affected areas [3].

Congo's health minister has called for international support, noting that hospitals in Ituri are already under strain [19]. The country plans to deploy rapid response teams across all nine affected health zones, but security conditions and road infrastructure in eastern Congo make rapid deployment difficult.

For Dr. Stafford and the six other Americans en route to Germany, the immediate prognosis depends on the severity of his infection and the quality of supportive care available. The Bundibugyo strain has historically carried a lower fatality rate than Zaire — roughly 25% versus 40–88% — but without specific therapeutics, outcomes depend heavily on early detection and intensive supportive treatment [6].

The broader question is whether the international community can mount an effective response to a strain that the post-2014 preparedness architecture was not designed to address — in a conflict zone, with reduced U.S. funding, and without the vaccines that made recent Zaire-strain outbreaks more manageable. The Bundibugyo virus has given the global health system a test it did not study for.

Source: WHO / CDC

Data as of May 18, 2026CSV